<SEC-DOCUMENT>0000879169-22-000007.txt : 20221101
<SEC-HEADER>0000879169-22-000007.hdr.sgml : 20221101
<ACCEPTANCE-DATETIME>20221101070521
ACCESSION NUMBER:		0000879169-22-000007
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20221101
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221101
DATE AS OF CHANGE:		20221101

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INCYTE CORP
		CENTRAL INDEX KEY:			0000879169
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				943136539
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12400
		FILM NUMBER:		221348466

	BUSINESS ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803
		BUSINESS PHONE:		3024986700

	MAIL ADDRESS:	
		STREET 1:		1801 AUGUSTINE CUT-OFF
		CITY:			WILMINGTON
		STATE:			DE
		ZIP:			19803

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE CORP
		DATE OF NAME CHANGE:	20030318

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE GENOMICS INC
		DATE OF NAME CHANGE:	20000710

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INCYTE PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19930902
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>incy-20221101.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:5f9a146d-6348-4371-8a3d-4e564d688239,g:c2c449a4-fd32-46b8-94e7-24c79eaedc0a,d:c5d0fdab0b4547a28797e9657a8242b0--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>incy-20221101</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF82Mi9mcmFnOjkwODg3M2EzMjlkYzQ2ZDE4MDUwMWYwMDgwNzExNDc2L3RhYmxlOjNkNTg4OTA3MGI1MDRlNjI4NWE1M2VlNjE2N2NmZDA4L3RhYmxlcmFuZ2U6M2Q1ODg5MDcwYjUwNGU2Mjg1YTUzZWU2MTY3Y2ZkMDhfMC0xLTEtMS0xMTUxMA_0d675174-dfda-44f9-aa06-386725dc3bad">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF82Mi9mcmFnOjkwODg3M2EzMjlkYzQ2ZDE4MDUwMWYwMDgwNzExNDc2L3RhYmxlOjNkNTg4OTA3MGI1MDRlNjI4NWE1M2VlNjE2N2NmZDA4L3RhYmxlcmFuZ2U6M2Q1ODg5MDcwYjUwNGU2Mjg1YTUzZWU2MTY3Y2ZkMDhfMS0xLTEtMS0xMTUxMA_1da41411-425c-4d4d-a699-6c2fe59ead7c">0000879169</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="incy-20221101.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879169</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic5d0fdab0b4547a28797e9657a8242b0_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjUy_45cdc38e-e821-4c48-a3c0-fe78d023cfa3">8-K</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8yNzQ4Nzc5MDcwNzQ0_2a678183-f87b-4469-af56-3db6b62d4a4b">November 1, 2022</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjU0_eb6621de-de48-44b5-8121-0e20f5898ec7">INCYTE CORPORATION</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6OGQ5YWVlYmE3YmUwNDVjM2I4NDJkYzBlYWJiMWFjZTIvdGFibGVyYW5nZTo4ZDlhZWViYTdiZTA0NWMzYjg0MmRjMGVhYmIxYWNlMl8wLTAtMS0xLTEwNQ_da3e8fa1-60b8-4bb8-8462-8fe3d696a83e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6OGQ5YWVlYmE3YmUwNDVjM2I4NDJkYzBlYWJiMWFjZTIvdGFibGVyYW5nZTo4ZDlhZWViYTdiZTA0NWMzYjg0MmRjMGVhYmIxYWNlMl8wLTEtMS0xLTEwNQ_c7846730-4bd4-4deb-9334-0db092d6903e">001-12400</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6OGQ5YWVlYmE3YmUwNDVjM2I4NDJkYzBlYWJiMWFjZTIvdGFibGVyYW5nZTo4ZDlhZWViYTdiZTA0NWMzYjg0MmRjMGVhYmIxYWNlMl8wLTItMS0xLTEwNQ_d0bf4c2f-f628-4bbb-82dc-a7b80c817622">94-3136539</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or Other Jurisdiction of<br/>Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6MGFlYjYwZDMzNzQxNDlmY2FlZTM2YjBkYTgzOWU0NDEvdGFibGVyYW5nZTowYWViNjBkMzM3NDE0OWZjYWVlMzZiMGRhODM5ZTQ0MV8wLTAtMS0xLTEwNS90ZXh0cmVnaW9uOjliYTlkZTAxZGVlYzRlYWQ5YWU4YmU1OGM1NGQyZDBkXzIxOTkwMjMyNTU2MTU_aba9bd2b-8ecd-4cdf-877b-29a3ac95f306">1801 Augustine Cut-Off</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6MGFlYjYwZDMzNzQxNDlmY2FlZTM2YjBkYTgzOWU0NDEvdGFibGVyYW5nZTowYWViNjBkMzM3NDE0OWZjYWVlMzZiMGRhODM5ZTQ0MV8wLTAtMS0xLTEwNS90ZXh0cmVnaW9uOjliYTlkZTAxZGVlYzRlYWQ5YWU4YmU1OGM1NGQyZDBkXzI3NDg3NzkwNjk1MTY_05f58a9f-01b1-405d-ab0d-8db8cc809666">Wilmington</ix:nonNumeric>, <ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6MGFlYjYwZDMzNzQxNDlmY2FlZTM2YjBkYTgzOWU0NDEvdGFibGVyYW5nZTowYWViNjBkMzM3NDE0OWZjYWVlMzZiMGRhODM5ZTQ0MV8wLTAtMS0xLTEwNS90ZXh0cmVnaW9uOjliYTlkZTAxZGVlYzRlYWQ5YWU4YmU1OGM1NGQyZDBkXzI3NDg3NzkwNjk1MjU_87550c58-9f83-4b7b-b264-457449edfd77">DE</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6MGFlYjYwZDMzNzQxNDlmY2FlZTM2YjBkYTgzOWU0NDEvdGFibGVyYW5nZTowYWViNjBkMzM3NDE0OWZjYWVlMzZiMGRhODM5ZTQ0MV8wLTEtMS0xLTEwNQ_3337f664-10b3-4eaa-8738-c48618cc96ae">19803</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjU1_d813fced-882b-4cd5-8a2a-d94dae592f30">302</ix:nonNumeric>) <ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjU2_d9c9b6a9-2985-4785-bfd7-1e1141da078b">498-6700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number,</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">including area code)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6Yjk5NzEwMGQ4OWY1NGQ4Yzk3ZTc3MWVmMzhhN2ZlM2EvdGFibGVyYW5nZTpiOTk3MTAwZDg5ZjU0ZDhjOTdlNzcxZWYzOGE3ZmUzYV8wLTAtMS0xLTEwNQ_c3c596f9-97dc-4325-9e06-85b28c34ea0e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6Yjk5NzEwMGQ4OWY1NGQ4Yzk3ZTc3MWVmMzhhN2ZlM2EvdGFibGVyYW5nZTpiOTk3MTAwZDg5ZjU0ZDhjOTdlNzcxZWYzOGE3ZmUzYV8yLTAtMS0xLTEwNQ_33b97f64-cbdd-4e7d-ae68-19a5a1bd33f9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6Yjk5NzEwMGQ4OWY1NGQ4Yzk3ZTc3MWVmMzhhN2ZlM2EvdGFibGVyYW5nZTpiOTk3MTAwZDg5ZjU0ZDhjOTdlNzcxZWYzOGE3ZmUzYV80LTAtMS0xLTEwNQ_f2c21fd3-4399-4ab1-904c-e60e42911aaa">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6Yjk5NzEwMGQ4OWY1NGQ4Yzk3ZTc3MWVmMzhhN2ZlM2EvdGFibGVyYW5nZTpiOTk3MTAwZDg5ZjU0ZDhjOTdlNzcxZWYzOGE3ZmUzYV82LTAtMS0xLTEwNQ_becdd942-ef18-4a7f-b87b-455494d768f8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:37.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6ZTZhNjM4YWRjMjIwNDdjNTk4M2QyOGQ0MGVlYzdmZGMvdGFibGVyYW5nZTplNmE2MzhhZGMyMjA0N2M1OTgzZDI4ZDQwZWVjN2ZkY18xLTAtMS0xLTEwNQ_3ef96073-58e8-4389-9e69-3f36ae012c81">Common Stock, $.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6ZTZhNjM4YWRjMjIwNDdjNTk4M2QyOGQ0MGVlYzdmZGMvdGFibGVyYW5nZTplNmE2MzhhZGMyMjA0N2M1OTgzZDI4ZDQwZWVjN2ZkY18xLTEtMS0xLTEwNQ_2d646d25-0c59-499b-8051-35ac6f7abc6c">INCY</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6ZTZhNjM4YWRjMjIwNDdjNTk4M2QyOGQ0MGVlYzdmZGMvdGFibGVyYW5nZTplNmE2MzhhZGMyMjA0N2M1OTgzZDI4ZDQwZWVjN2ZkY18xLTItMS0xLTEwNQ_19df7e75-f57c-41e8-ac5e-9e70ccd5e47a">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#8212;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8212;2 of this chapter).</span></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjU3_7ca6efbb-c978-44f9-b1d0-49db67b1818a">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic5d0fdab0b4547a28797e9657a8242b0_4"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;1, 2022, Incyte Corporation issued a press release announcing financial results for its third fiscal quarter ended September&#160;30, 2022. The full text of the press release is furnished as Exhibit 99.1.</span></div><div id="ic5d0fdab0b4547a28797e9657a8242b0_7"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Exhibits.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="incy-q32022xexx991.htm">Press release issued by Incyte Corporation dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="incy-q32022xexx991.htm">November 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="incy-q32022xexx991.htm">, 2022.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic5d0fdab0b4547a28797e9657a8242b0_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURE</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.326%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 1, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCYTE CORPORATION</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Christiana Stamoulis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Christiana Stamoulis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Executive Vice President and<br/>Chief Financial Officer</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>incy-q32022xexx991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i210032a211b74a7ba7370fb2486a2867_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div style="margin-top:12pt"><img alt="incy-20220802xex99d1001a.jpg" src="incy-20220802xex99d1001a.jpg" style="height:53px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR IMMEDIATE RELEASE</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Clinical Programs</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13pt">Total net product revenues grew to $713 million (+20% Y&#47;Y) as a result of strong Jakafi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ruxolitinib) and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Opzelura</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(ruxolitinib) cream</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> net product revenues </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13pt">Jakafi net product rev</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">enues of $620 million in Q3&#8217;22 (+13% Y&#47;Y)&#59; raising the bottom end of full year guidance to a new range of $2.38 to $2.40 billion</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13pt">Opzelura net pro</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">duct revenues of $38 million in Q3'22 driven by robust demand and broadening payer access&#59; launch in vitiligo underway </font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13pt">Pipeline progresses with positive povorcitinib data in hidradenitis suppurativa at EADV, oral PD-L1 update at SITC and the pending acquisition of Villaris Therapeutics and auremolimab, a novel anti-IL-15R&#946; mAb   </font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Scheduled Today at 8&#58;00 a.m. EDT</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WILMINGTON, Del. &#8211; November&#160;1, 2022</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Incyte (Nasdaq&#58;INCY) today reports 2022 third quarter financial results, and provides a status update on the Company&#8217;s clinical development portfolio. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Our total net product revenues grew 20% year over year led by strong Jakafi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ruxolitinib) performance and an increasing contribution from Opzelura</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ruxolitinib) cream</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Over 62,000 units of Opzelura were shipped in the quarter with growth fueled by both atopic dermatitis and vitiligo. This strong demand, coupled with an expansion of reimbursement coverage, positions Opzelura to become a meaningful long-term growth driver for Incyte,&#8221; said Herv&#233; Hoppenot, Chief Executive Officer, Incyte. &#8220;Additionally, our pipeline is progressing across Oncology and Dermatology, and we continue to execute on our strategy for growth and diversification with multiple updates on key programs expected over the next several months.&#8221;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Portfolio Updates</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MPNs and GVHD &#8211; key highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIMBER (Leadership In MPNs and GVHD BEyond Ruxolitinib) program&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Key LIMBER development programs, including combination trials of ruxolitinib with parsaclisib, INCB57643 (BET) and INCB00928 (ALK2), are ongoing. Additionally, the Prescription Drug User Fee Act (PDUFA) target action date for once-daily (QD) ruxolitinib extended release (XR) formulation is March 23, 2023.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Axatilimab in chronic graft-versus-host disease (cGVHD)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> AGAVE-201, a global pivotal Phase 2 trial of axatilimab in patients with cGVHD is ongoing with results expected mid-2023. A Phase 1&#47;2 combination trial of axatilimab with ruxolitinib in patients with newly-diagnosed cGVHD is in preparation and is expected to initiate in the first quarter of 2023.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indication and status</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QD ruxolitinib<br>(JAK1&#47;JAK2)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis, polycythemia vera and GVHD&#58; NDA under review</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib + parsaclisib <br>(JAK1&#47;JAK2 + PI3K&#948;)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis&#58; Phase 3 (first-line therapy) (LIMBER-313) <br>Myelofibrosis&#58; Phase 3 (suboptimal responders to ruxolitinib) (LIMBER-304)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib + INCB57643<br>(JAK1&#47;JAK2 + BET)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis&#58; Phase 2</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib + INCB00928<br>(JAK1&#47;JAK2 + ALK2)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis&#58; Phase 2</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib + CK0804</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(JAK1&#47;JAK2 + CB-Tregs)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myelofibrosis&#58; PoC (LIMBER-TREG108)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">axatilimab (anti-CSF-1R)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chronic GVHD&#58; Pivotal Phase 2 (third-line plus therapy) (AGAVE-201)</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Development collaboration with Cellenkos, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Clinical development of axatilimab in GVHD conducted in collaboration with Syndax Pharmaceuticals.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Hematology&#47;Oncology &#8211; key highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pemigatinib (Pemazyre</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August, Pemazyre was approved by the U.S. Food and Drug Administration (FDA) as the first and only targeted treatment for myeloid&#47;lymphoid neoplasms (MLNs) with FGFR1 rearrangement. MLNs with FGFR1 rearrangement are extremely rare and aggressive blood cancers and this approval demonstrates Incyte's commitment to improving and expanding treatments for patients living with rare blood cancers. Phase 2 open-label studies evaluating pemigatinib in glioblastoma and relapsed or refractory advanced non-small cell lung cancer are ongoing. </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indication and status</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">pemigatinib<br>(FGFR1&#47;2&#47;3)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Myeloid&#47;lymphoid neoplasms (MLN)&#58; approved by FDA<br>Cholangiocarcinoma (CCA)&#58; Phase 3 (FIGHT-302) <br>Glioblastoma&#58; Phase 2 (FIGHT-209) <br>Non-small cell lung cancer (NSCLC)&#58; Phase 2 (FIGHT-210) </font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">tafasitamab</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(CD19)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)&#58; Phase 2 (L-MIND)&#59; Phase 3 (B-MIND)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">First-line DLBCL&#58; Phase 3 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">frontMIND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relapsed or refractory follicular lymphoma (FL) and relapsed or refractory marginal zone lymphoma (MZL)&#58; Phase 3 (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inMIND</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Relapsed or refractory B-cell malignancies&#58; PoC with lenalidomide and plamotamab</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">parsaclisib<br>(PI3K&#948;)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warm autoimmune hemolytic anemia&#58; Phase 3 (PATHWAY)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">retifanlimab</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(PD-1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Squamous cell anal cancer (SCAC)&#58; Phase 3 (POD1UM-303) <br>MSI-high endometrial cancer&#58; Phase 2 (POD1UM-101, POD1UM-204) <br>Merkel cell carcinoma&#58; Phase 2 (POD1UM-201) <br>NSCLC&#58; Phase 3 (POD1UM-304)</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Development of tafasitamab in collaboration with MorphoSys.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Clinical collaboration with MorphoSys and Xencor, Inc. to investigate the combination of tafasitamab plus lenalidomide in combination with Xencor&#8217;s CD20xCD3 XmAb bispecific antibody, plamotamab.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Retifanlimab licensed from MacroGenics.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflammation and Autoimmunity (IAI) &#8211; key highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Dermatology</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opzelura growth coming from both atopic dermatitis (AD) and vitiligo in the U.S.&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Over 62,000 units of Opzelura were shipped in the third quarter with positive physician and patient experiences continuing to fuel uptake in AD. The launch in vitiligo is progressing well, contributing to the growth in overall demand. An increasing number of plans are adding Opzelura to formularies, helping to drive net product revenues to $38 million, a growth of 130% versus prior quarter. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ruxolitinib cream in other indications&#58; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte continues to expand the development of ruxolitinib cream into new indications as we seek to maximize the opportunity with Opzelura. Two Phase 2 trials evaluating ruxolitinib cream in lichen planus and lichen sclerosus are in preparation. Lichen planus is a recurrent inflammatory condition affecting the skin and mucosal surfaces and can result in itchy, purple bumps on the skin. Lichen sclerosus is a chronic inflammatory skin disease most commonly affecting women and can result in painful ulcers and intense itching. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Povorcitinib (INCB54707)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August, results from the randomized Phase 2 trial evaluating povorcitinib in patients with hidradenitis suppurativa (HS) were presented at the European Academy of Dermatology and Venereology (EADV) 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Congress. Based on the positive Phase 2 results, Incyte plans to initiate a Phase 3 study in HS by end of this year. </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indication and status</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib cream</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(JAK1&#47;JAK2)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AD&#58; Phase 3 pediatric study (TRuE-AD3)<br>Vitiligo&#58; Phase 3 (TRuE-V1, TRuE-V2)&#59; approved by FDA&#59; MAA under review<br>Lichen planus&#58; Phase 2 in preparation<br>Lichen sclerosus&#58; Phase 2 in preparation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ruxolitinib cream + UVB<br>(JAK1&#47;JAK2 + phototherapy)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vitiligo&#58; Phase 2</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">povorcitinib <br>(JAK1)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Hidradenitis suppurativa&#58; Phase 2b&#59; Phase 3 in preparation <br>Vitiligo&#58; Phase 2 <br>Prurigo nodularis&#58; Phase 2</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Novartis&#8217; rights for ruxolitinib outside of the United States under our Collaboration and License Agreement with Novartis do not include topical administration.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition of Villaris Therapeutics further complements dermatology portfolio&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October, Incyte announced an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company focused on the development of novel antibody therapeutics for vitiligo. Its lead asset, auremolimab (VM6) is a novel, ultra-humanized anti-IL-15R&#946; monoclonal antibody designed to target and deplete autoreactive resident memory T cells (T</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:1.41pt;vertical-align:baseline">RM</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) that has demonstrated efficacy as a treatment for vitiligo in preclinical models. Incyte will receive exclusive global rights to develop and commercialize auremolimab for all uses, including in vitiligo and other autoimmune and inflammatory diseases. IND-enabling studies are currently underway, and clinical development for auremolimab is expected to begin in 2023. The agreement is subject to clearance by the U.S. antitrust authorities under the Hart-Scott-Rodino Act and will become effective as soon as this condition has been met.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discovery and early development &#8211; key highlights</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte&#8217;s portfolio of other earlier-stage clinical candidates is included below. </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Modality</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Candidates</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Small molecules</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCB81776 (AXL&#47;MER), INCB99280 (PD-L1), INCB99318 (PD-L1), INCB106385 (A2A&#47;A2B), INCB123667 (CDK2)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Monoclonal antibodies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCAGN1876 (GITR), INCAGN2385 (LAG-3), INCAGN2390 (TIM-3), INCA00186 (CD73)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bi-specific antibodies </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INCA32459 (LAG-3xPD-1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Discovery collaboration with Agenus.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Development in collaboration with Merus</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered &#8211; key highlights</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indication and status</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ruxolitinib (JAK1&#47;JAK2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acute and chronic GVHD&#58; approved in Europe&#59; J-NDA under review</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">baricitinib (JAK1&#47;JAK2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AD&#58; Phase 3 (BREEZE-AD)&#59; approved in Europe and Japan <br>Severe AA&#58; Phase 3 (BRAVE-AA1, BRAVE-AA2)&#59; approved in the U.S., Europe and Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">capmatinib (MET)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">3</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NSCLC (with MET exon 14 skipping mutations)&#58; approved in the U.S., Europe and Japan</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Jakavi (ruxolitinib) licensed to Novartis ex-US.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Worldwide rights to baricitinib licensed to Lilly&#58; approved as Olumiant in multiple territories globally for certain patients with moderate-to-severe rheumatoid arthritis&#59; approved as Olumiant in EU and Japan for certain patients with atopic dermatitis.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Worldwide rights to capmatinib licensed to Novartis.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Third Quarter Financial Results</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial measures presented in this press release for the three and nine months ended September&#160;30, 2022 and 2021 have been prepared by the Company in accordance with U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;), unless otherwise identified as a Non-GAAP financial measure. Management believes that Non-GAAP information is useful for investors, when considered in conjunction with Incyte&#8217;s GAAP disclosures. Management uses such information internally and externally for establishing budgets, operating goals and financial planning purposes. These metrics are also used to manage the Company&#8217;s business and monitor performance. The Company adjusts, where appropriate, for expenses in order to reflect the Company&#8217;s core operations. The Company believes these adjustments are useful to investors by providing an enhanced understanding of the financial performance of the Company&#8217;s core operations. The metrics have been adopted to align the Company with disclosures provided by industry peers.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used in conjunction with and to supplement Incyte&#8217;s operating results as reported under GAAP. Non-GAAP measures may be defined an</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">d calculated differently by other companies in our industry.</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As changes in exchange rates are an important factor in understanding period-to-period comparisons, Management believes the presentation of certain revenue results on a constant currency basis in addition to reported results helps improve investors&#8217; ability to understand its operating results and evaluate its performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period over period. The Company calculates constant currency by calculating current year results using prior year foreign currency exchange rates and generally refers to such amounts calculated on a constant currency basis as excluding the impact of foreign exchange or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Financial Highlights</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except per share amounts)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total GAAP revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">823,303&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812,987&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,467,935&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,123,414&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total GAAP operating income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,376&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,410&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509,347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475,043&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Non-GAAP operating income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">167,271&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293,148&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">649,042&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659,019&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP net income</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,775&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,199&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,730&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,795&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,824&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,015&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,413&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP basic EPS</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.51&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP basic EPS</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.18&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP diluted EPS</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.73&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP diluted EPS</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.18&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.16&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.65&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue Details</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Details</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.596%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.605%"></td><td style="width:0.1%"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br>Change<br>(as reported)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(constant currency)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</font></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br>Change<br>(as reported)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(constant currency)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">1</font></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jakafi</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">619,595&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547,373&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,761,732&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,542,138&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Iclusig</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,929&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,522&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,222&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82,356&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pemazyre</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,414&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,562&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,429&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,924&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minjuvi</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,932&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">967&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,143&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,845&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">556&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,570&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,916&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Opzelura</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,140&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,454&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">713,010&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594,013&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,982,682&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673,974&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty revenues&#58;</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jakavi</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,808&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,655&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,386&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">242,295&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Olumiant</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,371&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,572&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,689&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">154,875&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(36&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tabrecta</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,114&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,747&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,178&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NM</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total royalty revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,293&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,974&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(40&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,253&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,440&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total net product and royalty revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">823,303&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">777,987&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,332,935&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,078,414&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Milestone and contract revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,000&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,000&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total GAAP revenues</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">823,303&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812,987&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,467,935&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,123,414&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">NM &#61; not meaningful</font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Percentage change in constant currency is calculated using 2021 foreign exchange rates to recalculate 2022 results.</font></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Product and Royalty Revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Product and royalty revenues for the quarter ended September&#160;30, 2022 increased over the prior year comparative period as a result of net product revenues increasing 20% year-over-year, primarily driven by increases in Jakafi and Opzelura net product revenues. Jakafi net product revenues for the quarter ended September&#160;30, 2022</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> increased 13% over the prior year comparative period, primarily driven by growth in patient demand across all indications. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Jakavi and Olumiant royalties for the quarter were impacted by unfavorable changes in foreign currency exchange rates, while Olumiant royalties were also impacted by a decrease in net product sales of Olumiant for use as a treatment for COVID-19 and a one-time deduction related to securing intellectual property rig</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">hts. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expense Summary</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.964%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br>Change</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br>Change</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP cost of product revenues</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,584&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,869&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,834&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,117&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP cost of product revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,521&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,965&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129,715&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89,863&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,007&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,945&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,576&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985,352&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP research and development</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">358,268&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308,675&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,004,372&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">901,170&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,460&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190,704&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,321&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513,358&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP selling, general and administrative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,474&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,050&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675,751&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443,886&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP (gain) loss on change in fair value of acquisition-related contingent consideration</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,893)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,910&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(852&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,198)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,068&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(193&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP (gain) loss on change in fair value of acquisition-related contingent consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">4</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP collaboration loss sharing</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,149&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(81&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,055&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,476&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%)</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Non-GAAP cost of product revenues excludes the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the cost of stock-based compensation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Non-GAAP research and development expenses exclude the cost of stock-based compensation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Non-GAAP selling, general and administrative expenses exclude the cost of stock-based compensation and legal settlements.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Non-GAAP (gain) loss on change in fair value of acquisition-related contingent consideration is null.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> GAAP and Non-GAAP research and development expense for the quarter ended September&#160;30, 2022 increased 15% and 16%, respectively, compared to the same period in 2021 primarily due to continued investment in our late stage development assets and certain upfront and milestone payments. Excluding the $33.5 million of upfront and milestone payments for the quarter ended September 30, 2022, GAAP and Non-GAAP research and development expense increased approximately 6% and 7%, respectively, compared to the same period in 2021.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> GAAP and Non-GAAP selling, general and administrative expenses for the quarter ended September&#160;30, 2022 increased 40% and 47%, respectively, compared to the same period in 2021, primarily due to expenses related to our dermatology commercial organization and activities to support the launch of Opzelura for the treatments of atopic dermatitis and vitiligo.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Financial Information</font></div><div style="margin-top:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating income</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> GAAP operating income for the quarter ended September&#160;30, 2022 decreased compared to the same period in 2021, primarily due to an increase in operating expenses partially offset by growth in net product revenues. </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents and marketable securities position</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2022 and December&#160;31, 2021, cash, cash equivalents and marketable securities totaled $3.0 billion and $2.3 billion, respectively.</font></div><div style="margin-bottom:6pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Financial Guidance</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte is tightening its full year 2022 guidance for Jakafi net product revenues to reflect strong performance of Jakafi and is revising the guidance range for other Hematology&#47;Oncology net product revenues to reflect unfavorable changes in foreign currency exchange rates. In addition, the Company is reaffirming its research and development guidance, which now also includes the upfront payment to Villaris, anticipated in the fourth quarter, and its selling, general and administrative expense guidance. Guidance does not include revenue from any potential new product launches or the impact of any potential future strategic transactions. Incyte&#8217;s updated guidance is summarized below.</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Previous</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jakafi net product revenues</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.38 - $2.40 billion</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$2.36 - $2.40 billion</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other Hematology&#47;Oncology net product revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$200 - $210 million</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$210 - $240 million</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Cost of product revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 &#8211; 7% of net product revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Cost of product revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5 &#8211; 6% of net product revenues</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Research and development expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,550 - $1,590 million</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Research and development expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$1,420 - $1,455 million</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GAAP Selling, general and administrative expenses</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$950 - $1,000 million</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP Selling, general and administrative expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</font></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$880 - $925 million</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unchanged</font></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Pemazyre in the U.S., EU and Japan and Iclusig and Minjuvi in the EU.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Adjusted to exclude the amortization of licensed intellectual property for Iclusig relating to the acquisition of the European business of ARIAD Pharmaceuticals, Inc. and the estimated cost of stock-based compensation.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Adjusted to exclude the estimated cost of stock-based compensation.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call and Webcast Information</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte will hold a conference call and webcast this morning at 8&#58;00 a.m. ET. To access the conference call, please dial 877-407-3042 for domestic callers or 201-389-0864 for international callers. When prompted, provide the conference identification number, 13733379.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If you are unable to participate, a replay of the conference call will be available for 90 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference identification number, 13733379. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conference call will also be webcast live and can be accessed at </font><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investor.incyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Incyte</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit </font><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and follow </font><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#64;Incyte</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Jakafi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (ruxolitinib)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jakafi is a first-in-class JAK1&#47;JAK2 inhibitor approved by the U.S. FDA for treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jakafi is also indicated for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea, in adults with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF and for treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jakafi is marketed by Incyte in the United States and by Novartis as Jakavi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ruxolitinib) outside the United States. Jakafi is a registered trademark of Incyte Corporation. Jakavi is a registered trademark of Novartis AG in countries outside the United States.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Opzelura&#8482; (ruxolitinib) Cream</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opzelura, a novel cream formulation of Incyte&#8217;s selective JAK1&#47;JAK2 inhibitor ruxolitinib, is the first and only topical JAK inhibitor approved for use in the United States, indicated for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Incyte announced the validation of the European Marketing Authorization Application (MAA) for ruxolitinib cream as a potential treatment for adolescents and adults (age &#62;12 years) with non-segmental vitiligo with facial involvement. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Opzelura is a trademark of Incyte. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#47;Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (tafasitamab) </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting immunotherapy. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide for the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tafasitamab) received conditional approval, in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tafasitamab is being clinically investigated as a therapeutic option in B-cell malignancies in several ongoing combination trials.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are registered trademarks of MorphoSys AG. Tafasitamab is co-marketed by Incyte and MorphoSys under the brand name Monjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S., and marketed by Incyte under the brand name Minjuvi</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe and Canada.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XmAb</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a registered trademark of Xencor, Inc.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Pemazyre</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (pemigatinib)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test*. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is also the first targeted treatment approved for use in the United States for treatment of adults with relapsed or refractory myeloid&#47;lymphoid neoplasms (MLNs) with FGFR1 rearrangement.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Europe, Pemazyre is approved for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is marketed by Incyte in the United States, Europe and Japan.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pemazyre is a trademark of Incyte Corporation.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">*</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Pemazyre</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(pemigatinib) &#91;Package Insert&#93;. Wilmington, DE&#58; Incyte&#59; 2020.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Iclusig</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> (ponatinib) tablets</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ponatinib (Iclusig</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) targets not only native BCR-ABL but also its isoforms that carry mutations that confer resistance to treatment, including the T315I mutation, which has been associated with resistance to other approved TKIs.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, Iclusig is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia (CML) who are resistant to dasatinib or nilotinib&#59; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate&#59; or who have the T315I mutation, or the treatment of adult patients with Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL) who are resistant to dasatinib&#59; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate&#59; or who have the T315I mutation.</font></div><div style="margin-top:12pt"><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Click here</font><font style="color:#4c4b53;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to view the Iclusig EU Summary of Medicinal Product Characteristics. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incyte has an exclusive license from Takeda Pharmaceuticals International AG to commercialize ponatinib in the European Union and 29 other countries, including Switzerland, UK, Norway, Turkey, Israel and Russia. Iclusig is marketed in the U.S. by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the historical information set forth herein, the matters set forth in this release contain predictions, estimates and other forward-looking statements, including any discussion of the following&#58; Incyte&#8217;s potential for long-term growth and diversification&#59; Incyte&#8217;s financial guidance for 2022, including its expectations regarding sales of Jakafi&#59; expectations with respect to demand for and uptake of Opzelura, including the Company&#8217;s ongoing discussions with payers&#59; expectations with regard to the NDA submission for once-daily ruxolitinib&#59; our and our collaborators&#8217; potential for receiving additional regulatory approvals within the next 1-2 years and the corresponding potential for launches of new products and&#47;or indications&#59; expectations regarding ongoing clinical trials and clinical trials to be initiated, including the LIMBER program, trials of axatilimab in cGVHD, a phase 3 trial of povorcitinib in hidradenitis suppurativa and phase 2 trials of ruxolitinib cream in lichen planus and lichen sclerosus&#59; expectations regarding our pending acquisition of Villaris Therapeutics and auremolimab&#59; and our expectations regarding 2022 newsflow items.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are based on the Company&#8217;s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to&#58; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development&#59; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules&#59; the effects of the COVID 19 pandemic and measures to address the pandemic on the Company&#8217;s clinical trials, supply chain and other third-party providers, sales and marketing efforts and business, development and discovery operations&#59; determinations made by the FDA, EMA, and other regulatory agencies&#59; the Company&#8217;s dependence on its relationships with and changes in the plans of its collaboration partners&#59; the efficacy or safety of the Company&#8217;s products and the products of the Company&#8217;s collaboration partners&#59; the acceptance of the Company&#8217;s products and the products of the Company&#8217;s collaboration partners in the marketplace&#59; market competition&#59; unexpected variations in the demand for the Company&#8217;s products and the products of the Company&#8217;s collaboration partners&#59; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for the Company&#8217;s products and the products of the Company&#8217;s collaboration partners&#59; sales, marketing, manufacturing and distribution requirements, including the Company&#8217;s and its collaboration partners&#8217; ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional products that become approved&#59; greater than expected expenses, including expenses relating to litigation or strategic activities&#59; variations in foreign currency exchange rates&#59; and other risks detailed in the Company&#8217;s reports filed with the Securities and Exchange Commission, including its annual report and the quarterly report on Form 10-Q for the quarter ended September 30, 2022.  Incyte disclaims any intent or obligation to update these forward-looking statements.</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;#&#160;&#160;&#160;#</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contacts</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Media</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investors</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Catalina Loveman</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+1 302 498 6171</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christine Chiou</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+1 302 274 4773</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">cloveman&#64;incyte.com</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">cchiou&#64;incyte.com</font></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i210032a211b74a7ba7370fb2486a2867_4"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except per share amounts)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">GAAP</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">713,010&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">594,013&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,982,682&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,673,974&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product royalty revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,293&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183,974&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,253&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,440&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone and contract revenues</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,000&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">823,303&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">812,987&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,467,935&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,123,414&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product revenues (including definite-lived intangible amortization)</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,584&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,869&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,834&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,117&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,007&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">334,945&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,084,576&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985,352&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">266,460&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">190,704&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729,321&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">513,358&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Gain) loss on change in fair value of acquisition-related contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,893)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,910&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,198)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,068&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration loss sharing</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,769&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,149&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,055&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,476&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total costs and expenses</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">684,927&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">577,577&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,958,588&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,648,371&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,376&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235,410&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">509,347&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">475,043&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,513&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,948&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,295&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,931&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(641)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(439)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,999)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,156)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on long term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(660)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,450)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72,142)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28,394)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">148,588&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,469&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448,501&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">450,424&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,813&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,730&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,302&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,694&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,775&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,739&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,199&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,730&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.51&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.41&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.75&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.50&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.82&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.40&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.73&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income per share&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,415&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,845&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,801&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,243&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,175&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,248&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223,626&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,113&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="i210032a211b74a7ba7370fb2486a2867_7"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,<br>2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br>2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,977,122&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,348,192&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618,188&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616,300&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">715,733&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723,920&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,679&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,548&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,133&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,938&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,199&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">165,302&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term investments</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149,124&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,266&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other intangible assets, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134,603&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,755&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,593&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155,593&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax asset</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,840&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467,538&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,510,214&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,933,352&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable, accrued expenses and other liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,043,975&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">885,081&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,588&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,267&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition-related contingent consideration</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,226,651&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,770,004&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,510,214&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,933,352&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><div id="i210032a211b74a7ba7370fb2486a2867_10"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCYTE CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECONCILIATION OF GAAP NET INCOME TO SELECTED NON-GAAP ADJUSTED INFORMATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, in thousands, except per share amounts)</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.023%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br>September 30,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br>September 30,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">GAAP Net Income</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,775&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,739&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,199&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">384,730&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#58;</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash stock compensation from equity awards (R&#38;D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,739&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,270&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,204&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,182&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash stock compensation from equity awards (SG&#38;A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,986&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,904&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,570&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,500&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash stock compensation from equity awards (COGS)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">2</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">679&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">520&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,967&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,102&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">3</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in fair value of equity investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">4</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">660&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,450&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,142&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,394&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of acquired product rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">5</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,384&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,384&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,152&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,152&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on change in fair value of contingent consideration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">6</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,893)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,910&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,198)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,068&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Legal settlements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">7</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,750&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,972&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax effect of Non-GAAP pre-tax adjustments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">8</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,607)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,175)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,309)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,759)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-GAAP Net Income</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,795&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,824&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">483,015&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">589,413&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.19&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.18&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.68&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.60&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.18&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.16&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.65&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares used in computing Non-GAAP net income per share&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,415&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,845&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221,801&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220,243&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224,175&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,248&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">223,626&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">222,113&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Included within the Milestone and contract revenues line item in the Condensed Consolidated Statements of Operations (in thousands) for the three and nine months ended September&#160;30, 2022 are milestones of $0 and $135,000, respectively, earned from our collaborative partners, as compared to milestones of $35,000 and $45,000, respectively, for the three and nine months ended September&#160;30, 2021. Included within the Research and development expenses line item in the Condensed Consolidated Statements of Operations (in thousands) for the three and nine months ended September&#160;30, 2022 are upfront consideration and milestones of $33,450 and $55,950, respectively, related to our collaborative partners, as compared to upfront consideration and milestones of $4,333 and $20,833, respectively, for the three and nine months ended September&#160;30, 2021.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the Cost of product revenues (including definite-lived intangible amortization) line item&#59; the Research and development expenses line item&#59; and the Selling, general and administrative expenses line item in the Condensed Consolidated Statements of Operations.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the Interest expense line item in the Condensed Consolidated Statements of Operations.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">4</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the Unrealized loss on long term investments line item in the Condensed Consolidated Statements of Operations.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the Cost of product revenues (including definite-lived intangible amortization) line item in the Condensed Consolidated Statements of Operations. Acquired product rights of licensed intellectual property for Iclusig is amortized utilizing a straight-line method over the estimated useful life of 12.5 years.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">6</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within the (Gain) loss on change in fair value of acquisition-related contingent consideration line item in the Condensed Consolidated Statements of Operations.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">7</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> As included within Selling, general and administrative expenses line item in the Condensed Consolidated Statements of Operations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Income tax effects of Non-GAAP pre-tax adjustments are calculated using the applicable statutory tax rate for the jurisdictions in which the charges are incurred, while taking into consideration any valuation allowances against related deferred tax assets.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>incy-20221101.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5f9a146d-6348-4371-8a3d-4e564d688239,g:c2c449a4-fd32-46b8-94e7-24c79eaedc0a-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:incy="http://www.incyte.com/20221101" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.incyte.com/20221101">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="incy-20221101_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="incy-20221101_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.incyte.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>incy-20221101_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5f9a146d-6348-4371-8a3d-4e564d688239,g:c2c449a4-fd32-46b8-94e7-24c79eaedc0a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_PreCommencementTenderOffer_4c1e0f85-f82d-40bc-a03c-32fa67a41ed7_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fca101fb-5b66-4df5-92e5-987cdc20bf22_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d8a325cb-be4b-4931-8fd0-57d2970fec34_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7c123702-5160-40d1-977c-c3f53cce4be6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_50b5dd90-34ab-4478-b5a3-ca47cf3bd454_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_db6dd1db-30a3-4cf5-a5a1-fff5a261a5f2_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_977f8400-a3a9-46da-95d5-8b72d0f5e5ca_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_a25bff9f-bc36-4604-b90d-e92f20454ef0_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f5fc0344-7ae7-43d3-bcd0-1b5163a81228_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_614921d7-b87e-497f-bec5-a2aa6465283c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c64bd34e-1f52-4e35-8a83-ba6ca964602f_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_d2972762-2e04-401d-9657-6a75f3ab6d5f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0f1a56e3-7a63-4ac0-8ad8-6f3e9aae7661_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2f74512d-de2f-404e-a747-7656de779732_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_15cf61d4-f85c-4a68-bd68-caf32dd1e819_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_88381b89-ad89-43aa-8f14-6b37ca27bc58_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b45f7639-1209-41e4-af9e-4c10fe186dd5_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_241ce830-381f-4ae4-96a8-a445657bfea0_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_dfc3b18a-6e82-4612-aeb5-837b26d93378_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7292809e-d10a-43e1-9680-baad10d98a9d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1d26c8ff-571a-4b12-9563-d37aa82fe8a8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_90edbb6a-54c0-446e-87c8-b0cba6d36242_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>incy-20221101_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:5f9a146d-6348-4371-8a3d-4e564d688239,g:c2c449a4-fd32-46b8-94e7-24c79eaedc0a-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.incyte.com/role/Cover" xlink:type="simple" xlink:href="incy-20221101.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.incyte.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d1b226b8-b45c-4d40-baca-5aa3a1c4d6eb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_DocumentType_d1b226b8-b45c-4d40-baca-5aa3a1c4d6eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3df48283-3d88-4b83-8d4c-b7336d5d542b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_DocumentPeriodEndDate_3df48283-3d88-4b83-8d4c-b7336d5d542b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_87968686-744f-4046-9a90-215cdddc0e4f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityRegistrantName_87968686-744f-4046-9a90-215cdddc0e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3a222515-b817-4749-baef-a2945b04d2b2" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3a222515-b817-4749-baef-a2945b04d2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_00b5b5d3-bfab-4c39-ab72-b761d8d64a17" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityFileNumber_00b5b5d3-bfab-4c39-ab72-b761d8d64a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_a4092c4e-0845-44a3-b2cf-bbee4799c3dc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityTaxIdentificationNumber_a4092c4e-0845-44a3-b2cf-bbee4799c3dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_be9c3d23-16a3-47dd-89ad-253ccae9981e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityAddressAddressLine1_be9c3d23-16a3-47dd-89ad-253ccae9981e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_69874a29-24b8-4353-9d4f-db927c607703" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityAddressCityOrTown_69874a29-24b8-4353-9d4f-db927c607703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_0513485d-5ed3-41a2-bfa0-b28bb69357a8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityAddressStateOrProvince_0513485d-5ed3-41a2-bfa0-b28bb69357a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_4a3394bf-c5ba-4d57-9625-7f5de505d91e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityAddressPostalZipCode_4a3394bf-c5ba-4d57-9625-7f5de505d91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a721f211-b999-419e-ab16-027899c41473" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_CityAreaCode_a721f211-b999-419e-ab16-027899c41473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_deb429a2-a832-4c8a-ab65-bcd8c7d7f170" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_LocalPhoneNumber_deb429a2-a832-4c8a-ab65-bcd8c7d7f170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_67f65e62-4e81-4e4e-bea1-87ed6091f78d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_WrittenCommunications_67f65e62-4e81-4e4e-bea1-87ed6091f78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_b309ce30-05ac-490a-b144-a47c0fe8b3b8" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_SolicitingMaterial_b309ce30-05ac-490a-b144-a47c0fe8b3b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_c5814849-81bd-47b2-9a42-2396967fab36" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_PreCommencementTenderOffer_c5814849-81bd-47b2-9a42-2396967fab36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_1d7cc20b-12a3-45e5-9e49-b4eda1e72359" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_1d7cc20b-12a3-45e5-9e49-b4eda1e72359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3943f47e-10ab-44f4-a2e8-ff3697863ab5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_Security12bTitle_3943f47e-10ab-44f4-a2e8-ff3697863ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_969a1820-0d88-4bb1-b288-c63d5cea701b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_TradingSymbol_969a1820-0d88-4bb1-b288-c63d5cea701b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2cf528b8-016c-4388-8a95-f7bbecf5b3f1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_SecurityExchangeName_2cf528b8-016c-4388-8a95-f7bbecf5b3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_567fc824-d2b2-4cbc-908a-ca26bfd48973" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityEmergingGrowthCompany_567fc824-d2b2-4cbc-908a-ca26bfd48973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c07e290e-96a5-4b93-8945-5e22bbfab1f0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_AmendmentFlag_c07e290e-96a5-4b93-8945-5e22bbfab1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ecb02c0d-0e9e-428a-9686-bb2889f1b80a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_e79f7297-5263-4a7b-9f40-81081b291835" xlink:to="loc_dei_EntityCentralIndexKey_ecb02c0d-0e9e-428a-9686-bb2889f1b80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>incy-20220802xex99d1001a.jpg
<TEXT>
begin 644 incy-20220802xex99d1001a.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !+ 0T# 2(  A$! Q$!_\0
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M+);&YE6$N5!RI57=QD?P9KO;J_T/P'X?A-Y>66A:-91I DEW.L$,2 !57<Q
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MHKMIQL?2O@C7)O$_@O0-9N(#:W&HZ?;W<D#*5,;21JY4@\C!.,&OEA5&F?\
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MN"^.O_))_$/_ %RC_P#1J5TX7^/3]5^9S8G^!/T?Y'>T445S'2%%%% 'P?\
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M91GWK,N?AQHUXC1W$NKSQ-]Z*36[UD8>A4S8(]B,5PI4^K?W?\$[VY]$OO\
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@:E%*4N9VG+?O;E7W:)]3TVBBBO$/:"BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm139993893232480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  01,  2022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INCYTE CORPORATION<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-12400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3136539<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1801 Augustine Cut-Off<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Wilmington<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">19803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">498-6700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INCY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>incy-20221101_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="incy-20221101.xsd" xlink:type="simple"/>
    <context id="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879169</identifier>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF82Mi9mcmFnOjkwODg3M2EzMjlkYzQ2ZDE4MDUwMWYwMDgwNzExNDc2L3RhYmxlOjNkNTg4OTA3MGI1MDRlNjI4NWE1M2VlNjE2N2NmZDA4L3RhYmxlcmFuZ2U6M2Q1ODg5MDcwYjUwNGU2Mjg1YTUzZWU2MTY3Y2ZkMDhfMC0xLTEtMS0xMTUxMA_0d675174-dfda-44f9-aa06-386725dc3bad">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF82Mi9mcmFnOjkwODg3M2EzMjlkYzQ2ZDE4MDUwMWYwMDgwNzExNDc2L3RhYmxlOjNkNTg4OTA3MGI1MDRlNjI4NWE1M2VlNjE2N2NmZDA4L3RhYmxlcmFuZ2U6M2Q1ODg5MDcwYjUwNGU2Mjg1YTUzZWU2MTY3Y2ZkMDhfMS0xLTEtMS0xMTUxMA_1da41411-425c-4d4d-a699-6c2fe59ead7c">0000879169</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjUy_45cdc38e-e821-4c48-a3c0-fe78d023cfa3">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8yNzQ4Nzc5MDcwNzQ0_2a678183-f87b-4469-af56-3db6b62d4a4b">2022-11-01</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjU0_eb6621de-de48-44b5-8121-0e20f5898ec7">INCYTE CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6OGQ5YWVlYmE3YmUwNDVjM2I4NDJkYzBlYWJiMWFjZTIvdGFibGVyYW5nZTo4ZDlhZWViYTdiZTA0NWMzYjg0MmRjMGVhYmIxYWNlMl8wLTAtMS0xLTEwNQ_da3e8fa1-60b8-4bb8-8462-8fe3d696a83e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6OGQ5YWVlYmE3YmUwNDVjM2I4NDJkYzBlYWJiMWFjZTIvdGFibGVyYW5nZTo4ZDlhZWViYTdiZTA0NWMzYjg0MmRjMGVhYmIxYWNlMl8wLTEtMS0xLTEwNQ_c7846730-4bd4-4deb-9334-0db092d6903e">001-12400</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6OGQ5YWVlYmE3YmUwNDVjM2I4NDJkYzBlYWJiMWFjZTIvdGFibGVyYW5nZTo4ZDlhZWViYTdiZTA0NWMzYjg0MmRjMGVhYmIxYWNlMl8wLTItMS0xLTEwNQ_d0bf4c2f-f628-4bbb-82dc-a7b80c817622">94-3136539</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6MGFlYjYwZDMzNzQxNDlmY2FlZTM2YjBkYTgzOWU0NDEvdGFibGVyYW5nZTowYWViNjBkMzM3NDE0OWZjYWVlMzZiMGRhODM5ZTQ0MV8wLTAtMS0xLTEwNS90ZXh0cmVnaW9uOjliYTlkZTAxZGVlYzRlYWQ5YWU4YmU1OGM1NGQyZDBkXzIxOTkwMjMyNTU2MTU_aba9bd2b-8ecd-4cdf-877b-29a3ac95f306">1801 Augustine Cut-Off</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6MGFlYjYwZDMzNzQxNDlmY2FlZTM2YjBkYTgzOWU0NDEvdGFibGVyYW5nZTowYWViNjBkMzM3NDE0OWZjYWVlMzZiMGRhODM5ZTQ0MV8wLTAtMS0xLTEwNS90ZXh0cmVnaW9uOjliYTlkZTAxZGVlYzRlYWQ5YWU4YmU1OGM1NGQyZDBkXzI3NDg3NzkwNjk1MTY_05f58a9f-01b1-405d-ab0d-8db8cc809666">Wilmington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6MGFlYjYwZDMzNzQxNDlmY2FlZTM2YjBkYTgzOWU0NDEvdGFibGVyYW5nZTowYWViNjBkMzM3NDE0OWZjYWVlMzZiMGRhODM5ZTQ0MV8wLTAtMS0xLTEwNS90ZXh0cmVnaW9uOjliYTlkZTAxZGVlYzRlYWQ5YWU4YmU1OGM1NGQyZDBkXzI3NDg3NzkwNjk1MjU_87550c58-9f83-4b7b-b264-457449edfd77">DE</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6MGFlYjYwZDMzNzQxNDlmY2FlZTM2YjBkYTgzOWU0NDEvdGFibGVyYW5nZTowYWViNjBkMzM3NDE0OWZjYWVlMzZiMGRhODM5ZTQ0MV8wLTEtMS0xLTEwNQ_3337f664-10b3-4eaa-8738-c48618cc96ae">19803</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjU1_d813fced-882b-4cd5-8a2a-d94dae592f30">302</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjU2_d9c9b6a9-2985-4785-bfd7-1e1141da078b">498-6700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6Yjk5NzEwMGQ4OWY1NGQ4Yzk3ZTc3MWVmMzhhN2ZlM2EvdGFibGVyYW5nZTpiOTk3MTAwZDg5ZjU0ZDhjOTdlNzcxZWYzOGE3ZmUzYV8wLTAtMS0xLTEwNQ_c3c596f9-97dc-4325-9e06-85b28c34ea0e">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6Yjk5NzEwMGQ4OWY1NGQ4Yzk3ZTc3MWVmMzhhN2ZlM2EvdGFibGVyYW5nZTpiOTk3MTAwZDg5ZjU0ZDhjOTdlNzcxZWYzOGE3ZmUzYV8yLTAtMS0xLTEwNQ_33b97f64-cbdd-4e7d-ae68-19a5a1bd33f9">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6Yjk5NzEwMGQ4OWY1NGQ4Yzk3ZTc3MWVmMzhhN2ZlM2EvdGFibGVyYW5nZTpiOTk3MTAwZDg5ZjU0ZDhjOTdlNzcxZWYzOGE3ZmUzYV80LTAtMS0xLTEwNQ_f2c21fd3-4399-4ab1-904c-e60e42911aaa">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6Yjk5NzEwMGQ4OWY1NGQ4Yzk3ZTc3MWVmMzhhN2ZlM2EvdGFibGVyYW5nZTpiOTk3MTAwZDg5ZjU0ZDhjOTdlNzcxZWYzOGE3ZmUzYV82LTAtMS0xLTEwNQ_becdd942-ef18-4a7f-b87b-455494d768f8">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6ZTZhNjM4YWRjMjIwNDdjNTk4M2QyOGQ0MGVlYzdmZGMvdGFibGVyYW5nZTplNmE2MzhhZGMyMjA0N2M1OTgzZDI4ZDQwZWVjN2ZkY18xLTAtMS0xLTEwNQ_3ef96073-58e8-4389-9e69-3f36ae012c81">Common Stock, $.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6ZTZhNjM4YWRjMjIwNDdjNTk4M2QyOGQ0MGVlYzdmZGMvdGFibGVyYW5nZTplNmE2MzhhZGMyMjA0N2M1OTgzZDI4ZDQwZWVjN2ZkY18xLTEtMS0xLTEwNQ_2d646d25-0c59-499b-8051-35ac6f7abc6c">INCY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGFibGU6ZTZhNjM4YWRjMjIwNDdjNTk4M2QyOGQ0MGVlYzdmZGMvdGFibGVyYW5nZTplNmE2MzhhZGMyMjA0N2M1OTgzZDI4ZDQwZWVjN2ZkY18xLTItMS0xLTEwNQ_19df7e75-f57c-41e8-ac5e-9e70ccd5e47a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101"
      id="id3VybDovL2RvY3MudjEvZG9jOmM1ZDBmZGFiMGI0NTQ3YTI4Nzk3ZTk2NTdhODI0MmIwL3NlYzpjNWQwZmRhYjBiNDU0N2EyODc5N2U5NjU3YTgyNDJiMF8xL2ZyYWc6YjMzMDkwNmE2NDdiNDQ1NGJiMTlhYmQxODhhOTU4OWIvdGV4dHJlZ2lvbjpiMzMwOTA2YTY0N2I0NDU0YmIxOWFiZDE4OGE5NTg5Yl8xMjU3_7ca6efbb-c978-44f9-b1d0-49db67b1818a">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M"_!\I93Y:-A#:_&;P^ _4$L#!!0    ( *DX856?H!OPL0(  .(,   -
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MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
MJ3AA5:K$(A8S 0  (@(   \   !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J
M'[ 6M"$-45Y VY"F#8V)]]"ZU"*)*\>%C:^?VZH:TE[VE-S9NMQ=%A?BTX'H
ME'QY%V)N:I%FGJ:QJ,';>$<-!)U4Q-Z*0CZFL6&P9:P!Q+MTFF6SU%L,9KD8
MM;:<W@(2* 0I*-D1>X1+_)UW,#ECQ ,ZE._<]'<')O$8T.,5RMQD)HDU75Z(
M\4I!K-L53,[E9C(,]L""Q1]ZUYG\M(?8,V(/'U:-Y&:6J6"%'*7?Z/6M>CR#
M+@^H%7I")\!K*_#,U#88CIV,IDAO8O0]C.=0XIS_4R-5%1:PIJ+U$&3HD<%U
M!D.LL8DF"=9#;E9T!N[RZ .;<L@F:NJF*9ZC#GA3#O9&3R54&*!\4YFHO/93
M;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0    ( *DX854D'INB
MK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.@S ,
MA:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4=VZ@
MMO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[NF:*<
M//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF**I9P
M6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    " "I.&%5
M99!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0A:\2
M95LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>CQ&P
MZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[E.O5
M,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0
MBJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:8P*I
ML0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X(;+U
M[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_
M 5!+ 0(4 Q0    ( *DX854'04UB@0   +$    0              "  0
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ J3AA5=5@;ZKN    *P(
M !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ J3AA59E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " "I.&%5")#Y8D<$  !_$   &
M        @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ J3AA59^@&_"Q @  X@P   T              ( !B@P  'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " "I.&%5EXJ[',     3 @  "P
M@ %F#P  7W)E;',O+G)E;'-02P$"% ,4    " "I.&%5JL0B%C,!   B @
M#P              @ %/$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MJ3AA520>FZ*M    ^ $  !H              ( !KQ$  'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ J3AA5660>9(9 0  SP,  !,
M             ( !E!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D
,"0 ^ @  WA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="incy-20221101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.incyte.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="incy-20221101.htm">incy-20221101.htm</File>
    <File>incy-20221101.xsd</File>
    <File>incy-20221101_lab.xml</File>
    <File>incy-20221101_pre.xml</File>
    <File>incy-q32022xexx991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "incy-20221101.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "incy-20221101.htm"
     ]
    },
    "labelLink": {
     "local": [
      "incy-20221101_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "incy-20221101_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "incy-20221101.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "incy",
   "nsuri": "http://www.incyte.com/20221101",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20221101.htm",
      "contextRef": "i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "role": "http://www.incyte.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "incy-20221101.htm",
      "contextRef": "i7b03a5a3ae0848b8b3a391b5e6184b93_D20221101-20221101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.incyte.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000879169-22-000007-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000879169-22-000007-xbrl.zip
M4$L#!!0    ( *DX857V:=J1WQ,  />!   1    :6YC>2TR,#(R,3$P,2YH
M=&WM76U7XLBV_GY^15WFWCGV6A8DE7?:]BQ'T,.,":VB#'QQ55(5"82$28*
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MR$*^'T3># N!E65)WJL4?]RK%%V[,9OM[['@!J79+.2?2BQ(1R&=5:,XXD!
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M&4^*95W"%>3$Y0]/A7S-,Y!M\F[4]<^:7JG;[X>/D/M/)R<7JPT\'GEUY7C
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MV.*2CDW-)::G@*\I@6OYZR^6H:H?7S:#X(=E^$4!>RYNP,-#>4.C![GH9V/
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M_IA2 >\SF;CYOMEB@ZK;ZO:<OJUVVF=]N]^80+N^TQJH-CF=-8]/)3O/OF-
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M.Z(?H.M=CR-+NB.@IIJ[#.T?1_'N@5_KWT^6JW^A*T44408\PEU ")4@\'D
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MLZ-_:,98R[U[6VN=D( ZW,>*^HP(\YDP$+TP4C=V73)B-""]V+'!AF.H-BD
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MS5,+1@N<3LR%<3< *W7G7O?^^=@%\ZA?G$Z5W"!'UG4%W@,FFQ-QXS"S99]
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MJ>.J)&V4GC;JJF(N'4*7PGW+#-Q46O(D\((C:6,(DE*V]+2QL>R98M/&(6W
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M8+!0'\!:8Z]+'_T C8U$D7"J2M5#ID@F]81"GOH./#'CC?P-U W]B==0 *%
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M*I^K\E]9:A*]>VLV3FX\2]A'/YI!['7I(Q@(2)+"-0ZY;^P'  /PEN,@8
MC&4(QQE4!4K["Z!0V^9LJO"9G:(J\D9BQK3;=8)!"JBYWD2Z&H4\]1VX[OE/
MA+JAC^II' !-_9S$L\'9_PX\ 2HM5&#(R+&<(3</8=YX?Q=L1%!4B2Y5!!QA
M&DL8P=G,JAFA$MN'^7A^E$XN!2>!V0T(+GWH W6@W@2H/V50%[8F/)OH> ?@
M9/%8T.0SW3B* _0<$<(],#KA@Q>B#>M['.!(ACSEKG$2 E!LON:,( #N83Q
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M-MV)6T^H=N<Z;^>IDF50?QM!_2Z$0;/)A4%+7XM>W!>PO" G9$G=>HL];MF
M_CT*6)H!\K5Z7U7(^5<N=GZC0'G\4UH6AY^O'._/^-%)GSC_6NY2FUW6J[7M
M/^,P2<_.ESP5M'"1A1&O5K!EP=S&2(+,HXG7 +]@6:V^UV68&\?(*76%A?,'
MZU@4EO52-OU.DQB?0#V3ON^",88U3.D"K'0!3\D"HKX3$F!?GNM((])\][;6
M/ %3GU8'57+^4"4//C"EA6PGJALGQE+(T.79Y38FMC4;C8JI-BJ&:NJ<RVU_
M@'1@\7M9P#/C=%6K&,U616W637X3"HG XS"$,9([J^2//O-09@R&0$28V^X_
M.EF)938)^,F+G"[P!1<97HQYN@K1C(9A&(U6<6AK#K:Z9.3'A()&BSV>E0=L
MQ'/R1:JC N@+&*;AI=)P&ID<T1T0G(_4<?D("-.62FPZ B@^]%DZ **HXJ0P
MRBH1OGH.<NE]A.F>F%R(6*S7U4J]63,R63KCX9EXPP$0PW5-KS1,K39-/\E<
M<-%\YAYC]K(XG5^ 4 RD/LQ#$\]X!5RES.>B=\3K!%&[L01.6&H7D1=E>D.U
M-KD 4>KH!U6'"Y,J2.M=9N@7AXEG*XAVQX^C)&VW6%H J]C('XZ+"=H1YF^?
M@5WQ!-)&J&'PVEV_ \S;<?SAA"DEZHT\M-6L&"D2^+#K>+Q$E=?F8*HREP(X
M03\.07P-6$0&S.:/(ULCPX/;U^LG B2T?#!A1LIDL:QGYRK[<C8D6HN!PR(:
MC/#Y@ [YU$"D?8:WIAGI\"IGK()QEF+EF5["C/K=,M-%(7B( [KKNZ[_M%-H
MO'M;-T\F664G(J4X.N0EF2(2:3<"J'IU.FPVL[)T;MCLQ:C9N[=:PSS9#H)G
MPX\<!?%WWX6Y>T[GN"!2.<F+YE*YZP1A!!95Q7(IV$:_M?^E\51/^("EUGVG
MXT0HZ+#H_A'K/$99P(-\/FL+\RVM8$:!:8&P]<#4_O+[KV>$UQQBWPL7*TW@
M*C8,P">>?(+SXCYT. +';8#U)UR^CC!$0NW8%5)Y"**<1@%<!D/4X85MFLZK
MH$2%&_@6+"@0'_T0Y*+<"/43VKO/X#?TW1&(I3Y A!*@;$J.;G\_SF 2DJ>^
M3_H4++8^M45E+;797S$V@<""/1^KB;!N/>#F/%C'/AC$5 S>']F!_WT$R*!*
M?DB'U]D"K@8<VAQ'?9A^)7#";V0P CW9=3H!,&%(CJX^'RM)31+J85'M.R)7
MGQ4LI(PJSU=P]5F@$J^B92GJCU M#SI^=FMRUS.( '4$OF-7 M8-J 74. (+
M-89)<A);@5A*0RNB>E-P76I*>3.\)5P:W'+M/Z++!M]#+K(?MR6REPDB%4AD
MSS%1)D0V ?T7I@[_!-2K)"]' ]9SD%#1C0R (1%U2+P)VD[]8)AT1:@FN'GY
MN0R7[2^(<\N//:!K%)ASYW/@]? -60__HA&7-AYY][9I-O63*3(_!9@,"F*?
MI#/%J),'5@>X@3@[U R#V,U<LZD"59 @HEA]KA&36[#"RZNQ=A?M'Z$;/!=L
M&^R^ KH)GIQE_:!NBL/94EB9UNK8VR49;D*?>:BB>_@-KJ2=71;78UC'VV-C
M=396FKD7AGT_B"JHT/EE>&4E:2&%3G)JHTU,"Q#)H^<#GW<=8S-:T1RUS[@E
M@L,Y@T'L^>B?@Q9WT#=?8*I@N_ @;2A:@8CRYM1\<4>\S54 WB&,QFV2=#E#
ML&RLP!ERU LST4&(^S@DPY]PW.P"MWS$T.!X8S2R2KZ&;*+]#A>J@XXC(H?)
MZ\8./L8B7+\'GKZ2%+Q/D(1XMZBE)@(4V.X'I@F$'\'5,,8$/)C)WS3J.QA#
M$):O-;)<'ZPT_*ZD$ @8CSU@#Y:B&R<7'KD!&PR#KZ+Y1*+@J.>!BK*2*.HC
M* &;SMP]N^(V#1J.[1C0%J2QEO9PZ*:AUJ.K=ON8TW2.91,A@##-%;&/2;C+
MXS%@[(96UOXBL6^/D K!Y==/4M(\%@A'0I[!B_Q:E_*^$8[WZ+N/O#MBX;V,
M!!=]@-&3'[CV$QH*7!./FVPM%/5Z!G9E;(O.MD##C+.*3L%C"8"4-,-8*Q":
M7]+G5SY/*)!1F>4!R(V#)"%#PF^5J%9$NQ3F3@<4;,>"F(T/XSD)WN[' ^S/
M!U+JLU4!L\;I.KCG/XI\=X0J_O1,:Y$(6%KH(Z'&DR 4;SBCJYJJ *,%P[Y_
M/PK'"24\PR!$6_.9G 4+*A&QS\0K6"BY*?(N+O]AGN4'2<+(Q +P=^XR<O^>
M_&?0[DAO?@5OGGD@L1EWL#];F E '2]M_Y-$NT+RJ6(QUR7N*'3&VT5TZ \C
M'O+B#7V0.AAAW2[#&!0\B]EV3CC(A<+:8)-T?'M4.6-#M.9@N:<P;N5*O,<F
MIT![D?_=L9QHA-;TZ>DQ'WS.@^#L!)A<U,,@F0B^P3.WQT57L1<SW:.2*ZR7
M]ZLV#-&\P*U8WYWOQUS$S8S*^[XMVL4%,9!D+@<:^TC/\'I<YJ&Y#EZ<S9YW
M)>5.''=,,_^./X40'/(MV8#D(K-GEY].+[E3PR7I$[AZ!+O(<=F;#QN+&[&G
M%G[CPA W!7MHCP$C#D#D#JCHI841[]2C Y3TG#2]A,:\.06ZM+B%0#@3\RY6
M0Q<CWD?M^].'8\P^<<+4.T^Z:6>@XSU*><J#R]W>I,'P(VY'TV3+&3>,,7LB
MBZ_CC55RZJ=-F;-'!/@FWS:@(\RJR/7VCF$4C(R/DTM$J=;8Q\6-%* "[OQV
MF,>Z#F_W+)*H'-Z-%C>D,6IV%)9!'@C_3R';M;K6KLH*(P2.,6C G$?1-#[+
M0D@)4?DAIRO)-KR0'FEV\L#/+"#EU;( #*XN1LM<-+'&.E:P-CGB$N#XU=Q=
M<-J?LDH[#,5=RMON*.GG[O2$Z.$N:2X*Y0]3L9V ;\#I$GM:BKZ)(>.R":14
MS^<CYW#.Q<,+^P+% %#))<+.LVFV:U;M&?P"-G,'CH>NQWY?^\N4<Q8"GU5F
M[,X*?*2/"=,")6@GX%%X;)8MT;4ZNB:J;<;MC2=0,!OH4L:\!NC">.,0/Z4>
MM0L?XY71DE61_5).0CY851@">"E$GI;IE37DL-L8[Y -T"PM4N;BN.X2Z?0;
M&+I\,S[=IQ]OP,_<I)KOSR1^S#!IH8N) '@/1BQB#[N)6Z)7M>L+HYW:CY1O
M=O) 8$1#> &6%_5]\$QZ#MP56(Z'7@X?%],L.X'?<;':(CG6HLN=).[%#?&#
M3HX^?_E\IQ\3\)EX""#MM XS"7CW]>18)V*#RK,2K4<]3,.L9.$,6&?T?S<4
M\1!1BC@8;Q,F5V4H9#4*QE30<1**V(G@0C>ESX423YYG3.9I>HYOSG,Z'9OO
MA F7W %;B?G@6H<#3/*\O$XWR9$LM4DJ+#J4+SQ1A:V0"7CGH?E,$$R&-";8
MON.X#B\ 0>AAE90%#'3TZ>'T^!7\C9TJ%-P_"L4)#R)7.AG<ZK-!MA5UX(E]
M39G8]^.XZN)TGA<.6]9GDYHLZM-(9++#='M!4G+(N0 N8-U4Q.L%AH$#S[H\
M@>IYM4#11=&DR2(2EY1QLB+FD?$LH]2&@24BW.!V'_,=0X+'_'"E:(A=2Q[:
M!4LE4XIA%-L\&Z[/;8,!:.1(Z/5Q2F125B=2VM)SZ@#O>%1IF(DTC#"&8Z$/
M"BI*#B M?!0Q#^8%T^:5O%_+U469%CDS=6DBSWQ7B]EHDXG_N\LF$QOU)S<*
MMDWN7BT&O EWDKQ[V]).;JGU#3,S+\"%""+XR3BI3I8)G_,V$%FF=ZUU@EFG
M:G'X],5*;-%;1@8?5@H^^%Y**]P&C\*BA"#2B9&C[2)XKP*-QXFW*_+?>>F%
M)[KT?3J]J[0_79(.<)"HE8S"L3'$;4:P1M&#C2-AFB0_\DX7&))PP'K%AA?8
MRBDU?/.9)V@(/!A:[2(;(LT'0P.JPYB'9V?[EDC92ISH_*@B+)-9V0__NBB\
M>721=AU3LI97BSD*4VYQ6CD"]F2(76%R023^$UKYPBT07]/[DW #6/7Q-U[L
M>71ZE=O[3^'+S]JS:9AP& SF.:[/OPCIGSZ0*VN=^T16& ,/#4@8=T+V5\P=
MCVR5HO!UD#R<5&/D-N<Y@,#_H*GV$:,)KV46'2T*Q]N^XX+UY@[[#JT@D 9^
MB.?R"G[&=BR\PE5$9CA  8ACX-WV_T':ES\$X&(PVSJ87LTL:VL.,:?3ENM8
MWPCP^$N&GFF9G9JQR;V87<IG()!'!X9"Y*4"X_PKN><'/O(F4)C3:CF8<W2;
MG+AP"CXF>);PPE!T2"F\3,RJ9:B72^E.LKQ%3N(#_<9L.MWA#RS2?-.I]A?D
MJ,E4[\R R3H^IA50X(0F86Z]E>B2K+PWKZ?N@>W^9H$+=RKDZ[\4<NT'3W2D
MD(<8_%OX]R(,*!-]U.[B,'1H-2_<GQ7L8'(H3_5R7>9Y3CR8W;<0JRZ!>?E9
MW$\>1A% )#BVD^!])D"RPU@OG0%ZV,51A[,Y_#-",K KE[[_C8,: P(HZHIB
M99Y_QS!:II?[#O;!XI#.]QG"@]+A&PAG%%9.<C N7(RP!=KX*J< ?DZNZ$:$
M^R]41)& B;D1I62=$I-."9PNNPF<W 1.80:G/*$BXK&O$M+@N.)/I!?"]4D?
M+JG6S1U#B\$]W^N):M4DFL@W@8 9@S#;&!*:96J8;G:^\\1IR'@^<GZ&:$-B
M^V<K-1D#UH-U\2515[0A$=7\XBT3]Z86(/XDRCL&J<K$?^-A!"R1KRV=-C83
MYL@FG>;JC6&6[C_2$:QX_A1PSFF'TNNS-G+FP!% YP<SP_(K-@5JS!?P)1HY
M%K/%?RT\6K>#82(?W\9G-840D5S*D3MN<043P/)KWH CV>434TLDC,>^1T2K
MY!MNB)9Z@=@H%.U")A&?G57<S9]AS!_F>U/C75T$Q S0C#&9I4"F@5&1_RC*
M<*9^BW@#//@M<L0V[R3&+B^N/IW?B;@T%C\F3Z$Q]YUBD:@HT2$6MB!!@2FL
M74/<*-JX//J@"S(-T'=L#-=YO(X:2X7Y-NHC%>7>_&D]]YKG=:\P!B@FWHP2
M-$(LEI7\$EI@U_EA_ /X .JQNH1C=;*_;7J\-?9IS%J<B0K:.& #GR]8#)X2
MT9R7\)/) 9-A%[/Y01<,#KXQ14ON7\WO4!FR%Y0,=UNRG(19HE0<%Q]-4B.2
M*(C&/Q-YC3V,Q(]8H!Z@YHLP>YJ'#3 CP:*XM4Y%>V@057Q_# 6]T\60 BI%
MI )WE!<3L9<_"3Y75<W3LO%MXKV<G'E?8J$'NWA6O A4S#ZE)Q6;Z43R^0^)
M@ #"#YV..TJRR6,OC'G+SF[L$BXPP[@+:M-)#J\?,,93";"^'K>S<W(<?48;
M@,];XC[QW;DH2<^()Y<EN)_WQL;M\&C$.RU[V*V!Y%XGNJ2*OEX"!1P>LV3R
MO+'&3U$+=(?0ZD(_@N3C%BE(/7"J63B>E*C+"U/CX_3F]XLSHK5 I7HVWR[D
MZ:)@_8 \X\@%O1:DW6"SF^91V>3L%2[ L5U%GR:X%N82:$*@8^R;.TH;!6.G
M"&%BC/-5$6<P7S#-DM9-24/QYRTILVZ5!'N6YW4@Y@ %@R33'XU]FZ558)_/
MV@HYOVHKN9GE57>/\>J!,>RFEVLG18@ =DP=BA(BQA?UG6%BC7"MRL\;"%,/
M ]'#,8"/C(T,U#$($R^S;1*$ 4BM$1)>2+LLREH+3T\G;Q.(]Z0_S'G@1Z_&
MJ-501/,V^\H4, +M !XKB8^('T3[\<@96[>Q)P09T/@CQ7@*1VXR2L[NW J8
M<BPU[NZ!>4CC20[!)\GD2;+)[Z(+F,P<?@&_9-")@U#L^6,'%)Y;UF/;60CG
M/67,>/C1BS%9(0Z$[\*Y#!B[P[O)PGS!,@J>.SFS7LSK@E^@=6%9YV3<6$[S
M9C?Y>($0!-B#9_P[.GL!A<G%.%T!,;"MTHC;(\= #ECHB.7L]>P:UW0=;#+#
MLB<%>'H\S1'QP$,@"5K3DW+RZT]_FS@J 4W47H9YD7:02S#(I,PD,<,RP KP
M$N4-(H!]%Y*$9QF&.3M3R"ZN1T'@@6<S#F=,XR)@0RY0N\ZX>Q#<=L_@+7PF
M?,3S]$WP>.(Z3?N)0.O"#L#Q,AK\*P:LL@!=*W$!EOP9''&BJ95_9Z2<W$5X
M*Q]X]Q ,&6R58Z@*MXRK)-VH1\GN4F<0<J1A[T7!'7['32$*\(V'-N9=1C^P
MDQ8.M^2/K\$N.2S8D>7W]MU;K:Z>Y/_.^JG0820!3!O82C#^!YY8*W;8,!\6
MF.!Y.&G^ D2J8>;C\#.)N& 9ANQ#^N$$Z 8[UW]P/#X=_M!),ECB&,W8^N,S
M%9?'3D-5%8Y#<HA8\N;D<I5?2H]3FKBF&]66.O^R6M7F7CO(87]P4ELA3ICZ
M,<'SQ?)&%@N<M96N2<45O5GHUC(L_R(YD&"14Q=G@J"4I##[M+%3&L$L/$HN
MP9J T98 21F6]P\-E+9.S%:3U+6&MF>K.^WS33H/[*"^X\=[MKH$=WK#)&:C
M84RL;D$.+*W@FGGHY N&BN4*]N4'(CP_9V6?9?S2H+*05UX"U,MG+1Y&M%M3
MYX>[<8Z._<\WC@Z3-G2J:UJG8=)&AS:,AMKMZ&:S3O5FO?&_YINBA<AWX#K-
MWKN^N#[][\,Y.;VYN[VY:S]<W%S/=3**,N73F^NS\^O[\S.8]?7]S>7%6?L!
MOMP_P#]7Y]</]^3F,[FY/1?+N2_\>HYBC\:VDVP<8O?A&(:S<1-=[-L/P></
M^[A[00>8VA$^+Z#= T?0;%9KK?K:72L-+NKS'WUIV)>OF:J<;,DF:ZS3PYYK
MJ;06L52$Q-F.K3)=4C';'7WH!XPWE(GZ(3G'D".JM8FHXSKLN))"YQK=F\6!
MLS['(!'97*(O?)AX\>"'\>I%CE7_X6H/"F3+1 H."C"2EEY)2XF FO(F#6$R
M;I[.EG#SY?N6?=^!&C!?VNW; [90GBW_!V30H=:W7@#^I%U)9FA9C'6[+PFV
M@L77WGR\8X_,B_DN?_-D$9TP;]'K41;[.'KQ9UBHT9?FNB[_;YKK"/_7*#C[
MI<5:0<*&"O%8-,V&RZQ<)3N5.JV%5OW3JU9X,AU0+]+2&IJAJ)HJ$F9>L\R4
MA)=8[E+,.?7*:0:7-%<>FJNU3* Y0]*<I+FM+4U36DU=J3=U2762ZK9(=?6&
MH;0:YNZH;DU.8<G,4W]$W6B4F:ES'45].4#,Y*?B49VF*GIK6?WZ MXW)>D6
M=3CW$TO-522#Q-)VL634@)=JDI>*C253-1737-:+72.6#BH(=.6XF,?NL>2(
M4D\TMGZ5LEW4>"T<Z?$*,OVD]&[%?F/)J"DPOD12H9&D22R5 $OFCI&T5H>V
M57!5^^!'O)CX]6[L8GDMY2#!IFXHAKJB4;YP@D]9S/6]PJRF*ZUF0V)V[S"K
M*V:]H;2,FL3M'N)6 XEL:BL&LS:+V]F)CUKMA<S'U2V^!<;84/**G&&99W@(
MJ7NG?I@T&DJ; ;TZB:\HZ6YRC 7&.*@8*1([;^0ZE3!'CL;MHFS6Q1:RK.(Z
MC[PS582GI6'U)AWXL)2_>0WY\6'%4VNF4FON<+]<QH 6":>VE&:])9%4:"1I
M9D-I&I*5"HXEM:%HVK(1CZ+&4XNNEN_FM$T^K 0AHVDJJKIBE*VD\9828LDP
ME9:Y8KQ,8FE;\EM1@9MJC;K$4Z'QU&K6%*.V;/JW3!%:3<_>,Q=^["G\F'H\
MH9KWE[8'X._R-L_@\!Z66ZO7ZXI9E[D-Q<:2UE*5ABI=IF)CJ:&W%$/7))8*
MC:6:9H#";4K'=BL*]^@+=;QCXOHA/S8C.:8 3TN@3D >J1OSTTIR!W=5TJ.%
MQ'D]/2:.[@GQU!D>>#XLG_A(UY1FRW@6;9<&?$$0I"NMI>O4)8ZVS$2:KFBM
MIF2BHB((NSW4E]7)T@E>=0\X?ZX35\W8U1?6<5B^KZ8TY&9AP7'44C13XJCH
M.%)KRVX'2!QMV4IM*>;2>P%%=7K+41UC/<LKE'4R C[UIJFT=%E-L7^8K34:
M"OPO,;MWF-645JVIU)HK.FD2MX7&;=UL*D9CV:T+62>S#S4><H:R3F81*7'A
M\9.VNX$_(/XPV8PYM!9F!LI)F5-5;"SI1DTQY:9,P;%44UN*8<ILWV)CR6S4
M%-7<8:.Y-6W-%%JUWD1]%A!'*-BC)%QT/+.)_7Z'*35-J>U!!^X]1Y+2,G>8
M/R5QM-B&NMZ2FS+%1I*IM(P=IHL>AM,:L8"%4;H'<UCNZE'=U&324V&Q8QHM
MB9W"8@?,G);$3Y'QH]7J.\'/(;BD7[V P33^9G:6O._Z7H^ .AV I_H(.A4+
MU ^LJ_91O:XN3G+2GMYVK41#,6L20<5%4$-7-%.7""HL@O2F8K3,G2#HH%($
MD\W4#NOZ <-N;(].B-GX\#6- T?TNTP9'#>-DLE'^XE976TIYM)U&!*SQ<>L
MB3RK%C*I3&+VE6=MJ(JI%[FM]E[[YK?K-1=*:ZT:-:4I=XL+CB3PR1N&;#!4
M;"1I1ETQU/(?0KW?6*K7E'IK7\YL+KJ'?LVB1+5NQL#9LS/0EUM[H=E,TW2E
MT=CG X$D!>\Y!3<U,+KV.:8B*7B_*=C@'9LD!4L*+BT%-\T5'-]#+ZDU8$FV
M'^-A0T6M!Y53W-H4#R%#>>QGDB$+>"<V)@^@.Z0Q#F'+XA,-'>LU,:L],W1F
MK;#0YHQ:K96_L[DDN#(17+/\^Q&2X,I#<%K5E!).$MPV"6[I38;B;>85VNH\
M<]PX8O9K:H3VC$EFK;#03 )V9_D;^4B"*Q/!+6UW2H*3!/<JNU-*.$EP6[4[
M=]_/JS";3W*,$HUQ"$[+/>X A20.F8T'Y5G^8!CC07C8#4[N%!WT& >[4Y0M
M=B_SNG5=5TQ-=FLK.I94I6E*+!4=2YK27+KH5&)I^[RD+]U56$:_UQ']7HBR
M2ML63-=-15NU>*-  95]QY(._+_# U\EEA;"DJ'4=7G:1=&QI"O:TF7PZX[H
MO8]HQV7PK^T\?OP%_DP%^,P:+&;HAPZ>&O,A8"Z-G$=V\N3843]92/XI\88/
MZO@1V@E]U&=S'YF>].+8: <.=5?6M;JH&<P@SP&0_XMS=.Q_OG%TF+2A4UW3
M.@V3-CJT8334;@<$89WJS7KC?QMOTF?Z68!T2'NLT@D8_5:AW8@%'ZC[1$?A
MY-H'CE?) WH:1@(4'W_I(*:>SS,_$@UZ,!BO/- G*=]BV$QYX\9,8R: +ZY/
M__MP3DYO[FYO[MH/%S?7DPN930@[G?+IS?79^?7]^1G,^OK^YO+BK/T 7SZU
M+]O7I^?D_M?S\X?[PJ_B*/9H;#M@2"H8CHSZ?@S#V>'QW)E/D1"&]5$VC%F;
M%P%8> KY,&0?T@\GMA,.73KZX'A\%ORADV2P1!X@;4_)(@XG<7E,]E55D'YB
MX2=O3BY7^:4I"2FN-;1JRYA_6:UJ<Z^]-*RF5]7F_$=?&O;E:Z9:W\QDC86&
M_8$7M40<] 6_2E#_=C1N\T<L(2+T;!BQ08<%Q% 5E*FZJNL+!.'W%1YGS$K
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M(_BG'PW<C_\_4$L! A0#%     @ J3AA5?9IVI'?$P  ]X$  !$
M     ( !     &EN8WDM,C R,C$Q,#$N:'1M4$L! A0#%     @ J3AA584^
M8)9E @  : <  !$              ( !#A0  &EN8WDM,C R,C$Q,#$N>'-D
M4$L! A0#%     @ J3AA5:F%@^U7"@  &%T  !4              ( !HA8
M &EN8WDM,C R,C$Q,#%?;&%B+GAM;%!+ 0(4 Q0    ( *DX856/7VC%J08
M -@P   5              "  2PA  !I;F-Y+3(P,C(Q,3 Q7W!R92YX;6Q0
M2P$"% ,4    " "I.&%5>KX$BCY7  !D*04 %@              @ $(*
L:6YC>2UQ,S(P,C)X97AX.3DQ+FAT;5!+!08     !0 % $@!  !Z?P     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
